Genmab teams up with BioNTech in immuno-oncology development and commercialisation agreement

Published: 19-May-2015
Research & Development

Makes an upfront payment of US$10m to BioNTech


Genmab of Denmark has entered into a technology agreement with German biotechnology company BioNTech to jointly research, develop and commercialise multiple bispecific antibodies for cancer immunotherapy.

The agreement will use technologies from both companies including BioNTech’s immunomodulatory antibodies and Genmab’s DuoBody technology platform.

Genmab will pay an upfront fee of US$10m to BioNTech and additional potential near-term payments of up to $5m if certain BioNTech assets are developed further.

  • Companies:
  • Genmab
  • BioNTech AG
See more

You may also like

Research & Development

Genmab finalises ProfoundBio acquisition

Read more
The $1.8bn acquisition allows Genmab exclusive access to ProfoundBio's clinical stage ADC Rina-S, as well as its ADC technology platforms

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. BioMarin Pharmaceutical expands Cork targeted therapy manufacturing facility with new lab The Irish facility is responsible for the development and commercialisation of therapies that address genetic conditions, and this expansion will allow the company to enhance its approved medicine production capacity
  3. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  4. ICROM has acquired HOLODIAG ICROM srl, an italian API CDMO, has acquired the French-based Contract Research Organization HOLODIAG sas specialized in solid state studies and crystallization services of small molecules
  5. Precise and efficient VARIO diaphragm pumps from Vacuubrand Advanced vacuum control for reproducible processes

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Genmab finalises ProfoundBio acquisition

The $1.8bn acquisition allows Genmab exclusive access to ProfoundBio's clinical stage ADC Rina-S, as well as its ADC technology platforms
Regulatory

ImaginAb announces supply agreement with Genmab

The non-exclusive worldwide agreement provides Genmab a license to use the company’s CD8 ImmunoPET imaging technology
Research & Development

Genmab and Synaffix enter into ADC license agreement

Genmab will be responsible for the research, development, manufacturing and commercialisation of any resulting ADC therapies
Ingredients

Pfizer and BioNTech announce early positive vaccine update

Collaboration has announced results from German Phase 1/2 COVID-19 vaccine study, including first T-Cell response data
Research & Development

BioNTech and Pfizer dose first cohort of Phase I/II COVID-19 vaccine trial

The trial is the first clinical trial of a COVID-19 vaccine candidate in Germany and there are plans to initiate trials in the US upon regulatory approval
Research & Development

Personalised cancer treatment 2.0: new combination strategy developed

Tumours often comprise groups of cancer cells that show differential drug sensitivities, one of the reasons that initially effective treatments usually do not lead to long-term benefit in patients
Ingredients

Tisotumab Vedotin co-developed by Genmab and Seattle Genetics

Genmab and Seattle Genetics announced Seattle Genetics has exercised its option to co-develop tisotumab vedotin
Subscribe now